About ARTHEx
ARTHEx is a company based in Valencia (Spain) founded in 2018. ARTHEx has raised $93.61 million across 9 funding rounds from investors including European Investment Bank, EIT Health and Bpifrance. ARTHEx offers products and services including Anti-miR Therapy. ARTHEx operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.
- Headquarter Valencia, Spain
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$93.61 M (USD)
in 9 rounds
-
Latest Funding Round
$40.64 M (USD), Series B
Sep 17, 2025
-
Investors
European Investment Bank
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ARTHEx
ARTHEx offers a comprehensive portfolio of products and services, including Anti-miR Therapy.
Investigational drug targeting microRNAs for Myotonic Dystrophy treatment
People of ARTHEx
Unlock access to complete
Unlock access to complete
Funding Insights of ARTHEx
ARTHEx has successfully raised a total of $93.61M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $40.64 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $40.6M
-
First Round
First Round
(01 Dec 2019)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Series B - ARTHEx | Valuation | Bpifrance | |
| May, 2023 | Amount | Series B - ARTHEx | Valuation | Columbus Venture Partners | |
| Mar, 2023 | Amount | Grant - ARTHEx | Valuation |
investors |
Investors in ARTHEx
ARTHEx has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, EIT Health and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Columbus Venture Partners is focused on biotechnology investment funds.
|
Founded Year | Domain | Location | |
|
AdBio Partners is engaged in early-stage life sciences investments.
|
Founded Year | Domain | Location | |
|
Invivo Partners is engaged in venture capital investments for early-stage healthcare companies.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ARTHEx
Financial Statements - ARTHEx
Arthex Comparisons
Competitors of ARTHEx
ARTHEx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
Latest news on Arthex
Frequently Asked Questions about ARTHEx
ARTHEx was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ARTHEx is headquartered in Valencia, Spain. It is registered at Valencia, Valencian Community, Spain.
ARTHEx is a funded company, having raised a total of $93.61M across 9 funding rounds to date. The company's 1st funding round was a Grant of $11.77M, raised on Dec 01, 2019.
ARTHEx was founded in 2018 in Valencia, Spain, within the biotechnology sector. Oligonucleotide-based treatments for neuromuscular disorders are developed, with emphasis on Myotonic Dystrophy. The lead candidate is engineered to block miRNAs that suppress MBNL12 expression, addressing the functional loss of MBNL proteins. Research and development activities are conducted to advance these therapies toward clinical applications.
ARTHEx's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
ARTHEx offers Anti-miR Therapy.
ARTHEx has 11 investors. Key investors include European Investment Bank, EIT Health, Bpifrance, European Union, and CDTI.